Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 2594 questions Show Answers
To ask the Scottish Government when it plans to open public swimming pools as part of the relaxation of lockdown restrictions.
To ask the Scottish Government when ice rinks will be permitted to open as part of the relaxation of lockdown restrictions.
To ask the Scottish Government when it expects to allow (a) baby massage and (b) baby yoga classes to resume as part of the relaxation of lockdown restrictions.
To ask the Scottish Government when all Scottish Natural Heritage sites will reopen to nursery and forest school classes.
To ask the Scottish Government what plans it has to relax the guidance on social distancing for under-12s to include all children who are transitioning from P7 to S1.
To ask the Scottish Government for what reasons schools and other local authority venues are not permitted to open in the evenings or on weekends for youth work or youth sports clubs, in light of a return to school in August 2020.
To ask the Scottish Government what action it has taken to ensure that any COVID-19 treatments that are developed from the £5 million that it has awarded to institutions for rapid research are openly licensed to ensure that they are affordable and accessible.
To ask the Scottish Government whether its electronic patient record (EPR) will be available to all practitioners in primary and secondary care.
To ask the Scottish Government what progress has been made with the roll out of electronic patient records (EPR).
To ask the Scottish Government, in light of reports that Dexamethasone is effective for the treatment of COVID-19, and that, because it is out of patent, it is inexpensive, whether will it use its Crown Use Licence powers to override any patents on other COVID-19 treatments to help ensure affordability and accessibility, including Remdesivir, which has reportedly being set a charge of $2,340 by its manufacturer for a course of treatment.